Cited by 745Liver Disease Diagnosis and TreatmentDiet, Metabolism, and DiseaseDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 261 of the 263 references it cites were found in a registry or an index.

Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases

Open access

Samuel, Varman T., Shulman, Gerald I.·2018·Cell Metabolism

DOI 10.1016/j.cmet.2017.08.002PMC PMC5762395

Open this paper in CoChat — free account Open PDF

Abstract

NAFLD is closely linked with hepatic insulin resistance. Accumulation of hepatic diacylglycerol activates PKC-ε, impairing insulin receptor activation and insulin-stimulated glycogen synthesis. Peripheral insulin resistance indirectly influences hepatic glucose and lipid metabolism by increasing flux of substrates that promote lipogenesis (glucose and fatty acids) and gluconeogenesis (glycerol and fatty acid-derived acetyl-CoA, an allosteric activator of pyruvate carboxylase). Weight loss with diet or bariatric surgery effectively treats NAFLD, but drugs specifically approved for NAFLD are not available. Some new pharmacological strategies act broadly to alter energy balance or influence pathways that contribute to NAFLD (e.g., agonists for PPAR γ, PPAR α/δ, FXR and analogs for FGF-21, and GLP-1). Others specifically inhibit key enzymes involved in lipid synthesis (e.g., mitochondrial pyruvate carrier, acetyl-CoA carboxylase, stearoyl-CoA desaturase, and monoacyl- and diacyl-glycerol transferases). Finally, a novel class of liver-targeted mitochondrial uncoupling agents increases hepatocellular energy expenditure, reversing the metabolic and hepatic complications of NAFLD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2017.08.002

Cites

261 of 261 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Mechanisms of fatty acid-induced inhibition of glucose uptake.
Boden, G., Chen, X., Ruiz, J., White, J. V., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117252 · Cited by 3,720
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416 · cited 1×
“A common SNP (rs738409, I148M) in the lipid droplet protein patatin-like phospholipase domain-containing protein 3 (PNLPA3, also called adiponutrin) has been associated with NAFLD and fibrosis (Romeo et al., 2008; Singal et al., 2014).”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Nonetheless, pioglitazone did improve several discrete metrics of hepatic inflammation (Sanyal et al., 2010).”
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,874 · cited 1×
“Perspective These include 3-phosphoinositide-dependent kinase-1 (PDK1) and mechanistic target of rapamycin complex 2 (mTORC2) (Guertin and Sabatini, 2007), which converge on Akt phosphorylation (Alessi et al., 1997; Guertin and Sabatini, 2007; Stephens et al., 1998).”
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · cited 2×
“and mechanistic target of rapamycin complex 2 (mTORC2) (Guertin and Sabatini, 2007), which converge on Akt phosphorylation (Alessi et al.”
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Self-citation

Flagged first, then by citations

Show all 263 references

2 of the 263 references couldn’t be matched to a known paper.

Sorted by citations

Items 401–500 of 743

Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective
Guo, J., Shi, C., Zhang, Q., Deng, W., Zhang, L., Chen, Q., Zhang, D., & Gong, Z. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221138676 · Cited by 14
Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease
Francque, S., & Ratziu, V. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.010 · Cited by 12
Integration of Transcriptomics and Lipidomics Profiling to Reveal the Therapeutic Mechanism Underlying Ramulus mori (Sangzhi) Alkaloids for the Treatment of Liver Lipid Metabolic Disturbance in High-Fat-Diet/Streptozotocin-Induced Diabetic Mice
Wang, F., Xu, S.-J., Ye, F., Zhang, B., & Sun, X. (2023) · Nutrients · doi:10.3390/nu15183914 · Cited by 13
“Furthermore, the glucose-converted DNL is almost metabolized to triglycerides (TGs) in the liver and further causes hypertriglyceridemia [36].”
Background
Peroxisome proliferator-activated receptor antagonists as emerging therapeutics in cancer treatment
Misal, S., Patil, V. M., Ramaa, C. S., & Lavecchia, A. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108693 · Cited by 14
Transient elevation of triacylglycerol content in the liver: a fundamental component of the acute response to exercise
Henderson, G. C., & Meyer, J. M. (2021) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00930.2020 · Cited by 11
Metabolic dysfunction-associated fatty liver disease increases the risk of type 2 diabetes mellitus in young Korean adults
Ha, J., Hong, O., Han, K., & Kwon, H.-S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111584 · Cited by 11
Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials
Wang, H., Ma, Q., Chen, Y., Luo, L., Ye, J., & Zhong, B. (2024) · Obesity Reviews · doi:10.1111/obr.13727 · Cited by 15
“8,9 However, it needs to be emphasized that metabolic-associated extrahepatic mortality far exceeds liver-related mortality in NAFLD.”
Background
Lipidome Changes Associated with a Diet-Induced Reduction in Hepatic Fat among Adolescent Boys with Metabolic Dysfunction-Associated Steatotic Liver Disease
Huneault, H. E., Chen, C., Cohen, C. C., Liu, X., Jarrell, Z. R., He, Z., DeSantos, K., Welsh, J. A., Maner-Smith, K. M., Ortlund, E. A., et al. (2024) · Metabolites · doi:10.3390/metabo14040191 · Cited by 11
Cilostazol Attenuates Hepatic Steatosis and Intestinal Disorders in Nonalcoholic Fatty Liver Disease
Min, T., Qiu, S., Bai, Y., Cao, H., Guo, J., & Su, Z.-Q. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116280 · Cited by 10
“In the process of pathological overnutrition, insulin resistance can promote liver gluconeogenesis, with glycerol and pyruvate as the substrates, thus promoting liver lipid synthesis and accelerating the progress of NAFLD [11].”
Background
RETRACTED ARTICLE: Association between the composite dietary antioxidant index and metabolic dysfunction-associated steatotic liver disease in adults: a cross-sectional study from NHANES 2017–2020
Yang, Z., Song, S., Li, L., Yuan, Z., & Li, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-63965-1 · Cited by 11
“NAFLD is linked to metabolic syndromes such as dyslipidemia, T2DM, obesity, and hypertension, which can lead to insulin resistance and adipose tissue dysfunction 46 .”
Retracted
Gut Bacteria-Derived Tryptamine Ameliorates Diet-Induced Obesity and Insulin Resistance in Mice
Lee, J., Jang, H.-R., Lee, D., Lee, Y., & Lee, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031327 · Cited by 13
“The liver plays a key physiological role as a major fat distributor by delivering dietary lipids to peripheral tissues in the form of very low-density lipoprotein and converting glucose to lipids via de novo lipogenesis [30].”
A systems biology approach to study non-alcoholic fatty liver (NAFL) in women with obesity
Meijnikman, A. S., Lappa, D., Herrema, H., Aydin, Ö., Krautkramer, K. A., Tremaroli, V., Olofsson, L. E., Lundqvist, A., Bruin, S. C., Acherman, Y. I. Z., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104828 · Cited by 12
“Furthermore, the hypoxia-inducible factor 1 (HIF-1) signaling pathway, which has previously been linked to NAFLD pathogenesis (Semenza 2007), was enriched in the liver of individuals with NAFL.”
Background
PACAP attenuates hepatic lipid accumulation through the FAIM/AMPK/IRβ axis during overnutrition
Luo, W., Dai, J., Liu, J., Huang, Y., Zheng, Z., Xu, P., & Ma, Y. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101584 · Cited by 11
“FAIM mediates the effect of PACAP on AMPK activation in vivo to improve hepatic lipid accumulation and insulin sensitivity Hepatic lipid accumulation induced by overnutrition causes sustained lipid stress in hepatocytes and contributes to the progression of MAFLD [1].”
Background
Up-regulated HOTAIR induced by fatty acids inhibits PTEN expression and increases triglycerides accumulation in HepG2 cells
Li, W., Chen, X., Lin, M., & Huang, D. (2017) · Food & Nutrition Research · doi:10.1080/16546628.2017.1412794 · Cited by 11
“NAFLD with early liver steatosis is a high-risk factor for HCC [7,8].”
BackgroundInfluential
Mice lacking have reduced signs of metabolic syndrome and non-alcoholic fatty liver disease
Ebert, C., Francisco, J. J., Liu, H., Draper, R., Modi, K., Hayward, M. D., Jones, B. K., Buiakova, O. I., McDonough, V. M., & Nickels, J. T. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000800 · Cited by 12
“It can progress to nonalcoholic steatohepatitis 3 fibrosis 3 cirrhosis3 hepatic cancer (10).”
BackgroundInfluential
What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
Targher, G. (2020) · Metabolites · doi:10.3390/metabo10100397 · Cited by 11
Inducible hepatic expression of CREBH mitigates diet-induced obesity, insulin resistance, and hepatic steatosis in mice
Krumm, C. S., Xu, X., Bare, C. J., Holman, C. D., Kersten, S., Dow, L. E., Lee, A.-H., & Cohen, D. E. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100815 · Cited by 11
“NAFLD is a common and important comorbidity of obesity with very limited treatment options (37).”
Background
Comprehensive study of the murine MASH models' applicability by comparing human liver transcriptomes
Ning, M., Lu, D., Teng, B., Liang, D., & Ren, P. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123723 · Cited by 10
Vanadium(IV)-Chlorodipicolinate Protects against Hepatic Steatosis by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammation
Wang, Y., Chen, R., Li, J., Zeng, G., Yuan, J.-T., Su, J., Wu, C., Lu, Z., Zhang, F., & Ding, W. (2022) · Antioxidants · doi:10.3390/antiox11061093 · Cited by 10
“FAAs are converted into TGs and stored in lipid droplets, some of which are exported into the blood as very-low-density lipoprotein, causing hypertriglyceridemia [48,49].”
Background
Differences in diacylglycerol acyltransferases expression patterns and regulation cause distinct hepatic triglyceride deposition in fish
Xiang, X., Ji, R., Han, S., Xu, X., Zhu, S., Li, Y., Du, J., Mai, K., & Ai, Q. (2024) · Communications Biology · doi:10.1038/s42003-024-06022-x · Cited by 10
Morin Prevents Non-Alcoholic Hepatic Steatosis in Obese Rats by Targeting the Peroxisome Proliferator-Activated Receptor Alpha (PPARα)
Al‐Harbi, L. N. (2024) · Life · doi:10.3390/life14080945 · Cited by 10
“These diets disrupt hormonal signaling, worsening appetite regulation and promoting overconsumption [10,11].”
Background
Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial
Al-Baiaty, F. D. R., Ishak, S., Zaki, F. M., Masra, F., Aziz, D. A. A., Zin, W. N. W. M., Hing, E. Y., Zaman, A., Wahab, N. A., Nawawi, K. N. M., et al. (2024) · BMC Pediatrics · doi:10.1186/s12887-024-04993-8 · Cited by 14
“Consequently, fat builds up within the liver [41].”
Background
Dodecanedioic acid prevents and reverses metabolic‐associated liver disease and obesity and ameliorates liver fibrosis in a rodent model of diet‐induced obesity
Angelini, G., Russo, S. L. M. L., Carli, F., Infelise, P., Panunzi, S., BERTUZZI, A., Caristo, M. E., Lembo, E., Calce, R., Bornstein, S. R., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202402108r · Cited by 11
Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
Traconis, A. P. M., Uribe, M., & Barbero-Becerra, V. J. (2024) · Cells · doi:10.3390/cells13242055 · Cited by 10
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 11
“The progression of MASLD also depends on obesity-related comorbidities [8].”
Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
Liang, C., Li, J., Tian, B., Tian, L., Liu, Y., Li, J., Xin, L., Wang, J., Fu, C., Shi, Z., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112298 · Cited by 12
The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease
Seko, Y., Yamaguchi, K., Yano, K., Takahashi, Y., Takeuchi, K., Kataoka, S., Moriguchi, M., & Itoh, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-22729-5 · Cited by 10
Phloretamide Prevent Hepatic and Pancreatic Damage in Diabetic Male Rats by Modulating Nrf2 and NF-κB
Al-Hussan, R., Albadr, N. A., Alshammari, G. M., Almasri, S. A., & Yahya, M. A. (2023) · Nutrients · doi:10.3390/nu15061456 · Cited by 10
“These data also support many other authors who have also shown similar results [55,56].”
Result
Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value
Li, Y.-Q., Xin, L., Zhao, Y., Li, S.-Q., & Li, Y.-N. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i6.786 · Cited by 10
Yao-Shan of traditional Chinese medicine: an old story for metabolic health
Yang, S., Yang, H., & Zhang, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1194026 · Cited by 10
“NAFLD, which is viewed as the hepatic manifestation of metabolic syndrome, is associated with obesity and encompasses a broad spectrum of conditions, from simple steatosis [always refers to nonalcoholic fatty liver (NAFL)], through nonalcoholic steatohepatitis (NASH), to fibrosis and cirrhosis, and ultimately hepatoce…”
Background
Dual-Tuned Coaxial-Transmission-Line RF Coils for Hyperpolarized 13 C and Deuterium 2 H Metabolic MRS Imaging at Ultrahigh Fields
Payne, K., Zhao, Y., Bhosale, A. A., & Zhang, X. (2023) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2023.3341760 · Cited by 10
“The proposed dual-tuned RF coils reveal highly effective magnetic field obtained from both proton and heteronuclear signal which is crucial for accurate and detailed imaging.”
Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease
Wang, J., Yang, N., & Xu, Y. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500137 · Cited by 10
Total-body PET Imaging
Chondronikola, M., & Sarkar, S. (2020) · PET Clinics · doi:10.1016/j.cpet.2020.09.001 · Cited by 10
Prolonged Antibiotic Exposure during Adolescence Dysregulates Liver Metabolism and Promotes Adiposity in Mice
Carson, M. D., Warner, A. J., Geiser, V. L., Hathaway‐Schrader, J. D., Alekseyenko, A. V., Marshall, J. L., Westwater, C., & Novince, C. M. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.02.014 · Cited by 10
Relation between Body Composition Trajectories from Childhood to Adolescence and Nonalcoholic Fatty Liver Disease Risk
Alberti, G., Faune, M., Santos, J. L., Barbieri, F. D., García, C., Pereira, A. P. R., Becerra, F., & Gana, J. C. (2024) · Nutrients · doi:10.3390/nu16060785 · Cited by 9
“Insulin resistance can trigger an increase in de novo lipogenesis in the liver, leading to a reduction in β -oxidation, ultimately resulting in the accumulation of fat in the liver [7].”
Background
Association between TyG related parameters and metabolic dysfunction associated fatty liver disease among nondiabetic individuals
Zhang, Q., Liu, Z., Zhang, J., Yang, S., & Liu, L. (2025) · Scientific Reports · doi:10.1038/s41598-024-84917-9 · Cited by 9
Honeysuckle-derived exosome-like nanovesicles ameliorate metabolic-associated fatty liver disease by modulating gut microbiota and its metabolites
Li, P., Wu, Q., Zhou, Y., Hu, X., Tang, Y., Wang, Y.-Y., Fan, W., Shan, Y., Yu, K., Wang, J., et al. (2025) · Nano Research · doi:10.26599/nr.2025.94907986 · Cited by 9
Dihydrotrichodimerol Purified from the Marine Fungus Acremonium citrinum Prevents NAFLD by Targeting PPARα
Liu, J., Gao, S., Zhou, W., Chen, Y., Wang, Z., Zeng, Z., Zhou, H., & Lin, T. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.2c00990 · Cited by 9
At the dawn of potent therapeutics for fatty liver disease – introducing the miniseries on promising pharmacological targets for NASH
Ratziu, V., & Tacke, F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.003 · Cited by 9
MAD2-Dependent Insulin Receptor Endocytosis Regulates Metabolic Homeostasis
Park, J., Hall, C., Hubbard, B. T., LaMoia, T. E., Gaspar, R. C., Nasiri, A. R., Li, F., Zhang, H., Kim, J., Haeusler, R. A., et al. (2023) · Diabetes · doi:10.2337/db23-0314 · Cited by 9
Self-citation
Protective role of germinated mung bean against progression of non-alcoholic steatohepatitis in rats: A dietary therapy to improve fatty liver health
Alshammari, G. M., Balakrishnan, A., & Chinnasamy, T. (2018) · Journal of Food Biochemistry · doi:10.1111/jfbc.12542 · Cited by 9
Biomolecular Component Analysis of Phospholipids Composition in Live HeLa Cells
Levchenko, S. M., & Qu, J. (2018) · Biosensors · doi:10.3390/bios8040123 · Cited by 9
Adipokinome Signatures in Obese Mouse Models Reflect Adipose Tissue Health and Are Associated with Serum Lipid Composition
Knebel, B., Fahlbusch, P., Poschmann, G., Dille, M. A., Wahlers, N., Stühler, K., Hartwig, S., Lehr, S., Schiller, M., Jacob, S., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102559 · Cited by 9
Effects of single parenthood on mothers' behavior, morphology, and endocrine function in the biparental California mouse
Zhao, M., Harris, B. N., Nguyen, C. T. Y., & Wendy Saltzman, A. (2019) · Hormones and Behavior · doi:10.1016/j.yhbeh.2019.05.005 · Cited by 8
NLRP3 sparks the Greek fire in the war against lipid‐related diseases
Jiang, S., Xiao, H., Wu, Z. B., Yang, Z. P., Ding, B., Jin, Z., & Yang, Y. (2020) · Obesity Reviews · doi:10.1111/obr.13045 · Cited by 9
Maternal hepatic adaptations during obese pregnancy encompass lobe-specific mitochondrial alterations and oxidative stress
Grilo, L. F., Martins, J. D., Diniz, M. S., Tocantins, C., Cavallaro, C. H., Baldeiras, I., Cunha‐Oliveira, T., Ford, S. P., Nathanielsz, P. W., Oliveira, P. J., et al. (2023) · Clinical Science · doi:10.1042/cs20230048 · Cited by 10
Deregulation of Hepatic Mek1/2–Erk1/2 Signaling Module in Iron Overload Conditions
Tangudu, N. K., Buth, N., Strnad, P., Cirstea, I. C., & Spasić, M. V. (2019) · Pharmaceuticals · doi:10.3390/ph12020070 · Cited by 9
Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population
Narankiewicz, D., Ruiz-Nava, J., Buonaiuto, V. A., Ruiz-Moreno, M. I., Lopez-Carmona, M. D., Perez-Belmonte, L. M., Gómez‐Huelgas, R., & Bernal-López, M. R. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103518 · Cited by 7
“On the other hand, increased liver enzymes concentrations and triglyceride levels have been proposed as metabolic factors that could explain the differences between metabolically healthy and abnormal phenotype [35].”
Background
Inhibition of mGluR5 ameliorates lipid accumulation and inflammation in HepG2 cells
Zeng, S., Tao, M., Yuan, L., Zhang, L., & Luo, X. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.02.033 · Cited by 8
Protease activated receptor 2 as a novel druggable target for the treatment of metabolic dysfunction-associated fatty liver disease and cancer
Villano, G., & Pontisso, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1397441 · Cited by 8
Disrupted minor intron splicing activates reductive carboxylation-mediated lipogenesis to drive metabolic dysfunction–associated steatotic liver disease progression
Fu, Y., Peng, X., Song, H., Li, X., Zhi, Y., Tang, J. T., Liu, Y., Chen, D., Li, W., Zhang, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186478 · Cited by 8
Metabolic dysfunction-associated steatotic liver disease in people with HIV
Gattu, A. K., & Fourman, L. T. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000952 · Cited by 10
“In adipose tissue, insulin resistance predisposes to lipolysis, through cytokines such as tumor necrosis factor-alpha (TNF a ) [26,34 – 36].”
Hepatic Lipidomics Unravels the Lipid‐Lowering and Anti‐Obesity Efficacy of Diacylglycerol Oil: Mechanistic Insights From High‐Fat Diet‐Induced Obese Mice
Shi, L., Liu, Y., Yan, Y., Bian, D., Jin, J., Jin, Q., Yan, J., & Wang, X. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70395 · Cited by 9
“Lipids, as bioactive signaling molecules, play a vital role in metabolic homeostasis, and their dysregulated metabolic network is a hallmark of metabolic disorders such as obesity and non-alcoholic fatty liver disease (Fahy et al. 2011; Perreault et al. 2016; Samuel and Shulman 2018).”
Gender‐specific data‐driven adiposity subtypes using deep‐learning‐based abdominal CT segmentation
Zou, X., Zhou, X., Li, Y., Huang, Q., Ni, Y., Zhang, R., Zhang, F., Wen, X. L., Cheng, J., Yuan, Y., et al. (2023) · Obesity · doi:10.1002/oby.23741 · Cited by 8
“Ectopic fat deposition, e.g., in the liver and skeletal muscle, is highly associated with increased VAT [5, 6].”
Background
The Effects of Soy Products and Isoflavones in Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
de Piano, A., Masquio, D. C. L., & Dâmaso, A. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813822-9.00008-4 · Cited by 8
The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC)
Venniyoor, A., Farsi, A. M. A., & Bahrani, B. J. A. (2021) · Cureus · doi:10.7759/cureus.17320 · Cited by 8
“However, it is clear that the vast majority of NAFLD is associated with metabolic and lifestyle disorders [13]).”
Background
Nonalcoholic Steatohepatitis in Children
Xanthakos, S. A. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.05.001 · Cited by 8
Improved lipogenesis gene expression in liver is associated with elevated plasma angiotensin 1-7 after AT1 receptor blockade in insulin-resistant OLETF rats
Godoy-Lugo, J. A., Mendez, D. A., Rodríguez, R., Nishiyama, A., Nakano, D., Soñanez‐Organis, J. G., & Ortiz, R. M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111729 · Cited by 9
Hypolipidemic effects of the fermented soymilk with a novel Lactiplantibacillus plantarum strain X7021 on mice via modulating lipid metabolism and gut microbiota
Jiang, C., Liu, Y., Wang, Y., Su, E., Du, L., Ya-jie Tang, A., Xie, J., & Wei, D. (2022) · International Journal of Food Science & Technology · doi:10.1111/ijfs.15793 · Cited by 8
Intestinal microbiota in the treatment of metabolically associated fatty liver disease
Wang, J.-S., & Liu, J. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i31.11240 · Cited by 8
Isolated murine skeletal muscles utilize pyruvate over glucose for oxidation
Khattri, R. B., Puglise, J. M., RYAN, T. E., Walter, G. A., Merritt, M. E., & Barton, E. R. (2022) · Metabolomics · doi:10.1007/s11306-022-01948-x · Cited by 8
“…of 13C-enriched substrates and chemical selectivity nature of carbon-13 NMR makes it a valuable tool for delving into normal metabolism (Cohen, 1983) as well as disrupted metabolic homeostasis associated with diseases such as diabetes and nonalcoholic fatty liver diseases (Samuel & Shulman, 2018).”
Background
Study on the mechanism of Shuganzhi Tablet against nonalcoholic fatty liver disease and lipid regulation effects of its main substances in vitro
Tang, J. T., Wang, L., Shi, M., Feng, S., Zhang, T., & Han, H. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116780 · Cited by 8
Hepatoprotective Effect of Lactiplantibacillus plantarum DSR330 in Mice with High Fat Diet-Induced Nonalcoholic Fatty Liver Disease
Lee, N., Lee, Y., Shin, D.-S., Ra, J., Choi, Y., Ryu, B. H., Lee, J., Park, E., & Paik, H. (2023) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2310.10026 · Cited by 8
“The liver plays a major role in whole-body lipogenesis, cholesterol metabolism, and gluconeogenesis [1].”
Background
Treatment potential of LPCN 1144 on liver health and metabolic regulation in a non-genomic, high fat diet induced NASH rabbit model
Comeglio, P., Sarchielli, E., Filippi, S., Cellai, I., Guarnieri, G., Morelli, A., Rastrelli, G., Maseroli, E., Cipriani, S., Mello, T., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01522-7 · Cited by 7
Adipose tissue-derived metabolite risk scores and risk for type 2 diabetes in South Asians
Gadgil, M. D., Cheng, J. Q., Herrington, D. M., Kandula, N. R., & Kanaya, A. M. (2024) · International Journal of Obesity · doi:10.1038/s41366-023-01457-4 · Cited by 7
“Ectopic fat, speci ﬁ cally intrahepatic fat and visceral adiposity, and impaired glycemia likely have bidirectional effects once present; the presence of each contributes to exacerbation of its counterpart [27].”
Repression of the ERRγ-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injury
Wang, L., Dong, W., Fan, L., Kong, H., Liang, S., Huang, Z., Chen, J., Zhi, S., Xu, S., Qiu, Q., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001282 · Cited by 7
Myeloid TGF-β signaling shapes liver macrophage heterogeneity and metabolic liver disease pathogenesis
Meng, Z., Qiu, X., Chen, Z., Lee, Y.-T., Zhou, L., Lu, Y., Liu, T., Li, S., Lévi, B., Gallagher, K. A., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101488 · Cited by 7
Schisandrin B alleviates metabolic associated fatty liver disease by regulating the PPARγ signaling pathway and gut microbiota in mice
Wan, J., Lang, C., Gao, M., Liu, F., Feng, X., Li, H., Wang, C., & Sun, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1583307 · Cited by 7
Meta-analysis of the effectiveness of fecal microbiota transplantation in the treatment of metabolic-associated fatty liver disease: A systematic review based on liver inflammation indicators and fat content
He, C., Zhou, F., & Fang, X. (2026) · Medicine · doi:10.1097/md.0000000000046886 · Cited by 7
“[5,6] The continuous increase in liver inflammation and fat content is not only a core feature of the pathological process of MASLD, but also a key indicator for assessing disease severity, predicting disease progression, and evaluating treatment efficacy.”
Acute exercise in mice transiently remodels the hepatic lipidome in an intensity-dependent manner
Henderson, G. C., Tenorio, V. M., & Tuazon, M. A. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01395-4 · Cited by 7
Black and Yellow Soybean Consumption Prevents High‐Fat Diet‐Induced Obesity by Regulating Lipid Metabolism in C57BL/6 Mice
Jeong, E. W., Dhungana, S. K., Yang, Y. S., Baek, Y., Seo, J., Kang, B. K., Jung, C.-S., Han, S., & Lee, H. G. (2023) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2023/6139667 · Cited by 7
“Consumption of large quantities of HFD results in fat accumulation in the liver, thereby damaging it and potentially exposing it to nonalcoholic fatty liver disease [3, 27].”
Background
Alginate oligosaccharides improve high-fat induced hepatic steatosis via PGC-1α-mediated lipophagy and fatty acid β-oxidation pathway
Li, Z., Zhao, M., Ji, X., Fan, L., & Zhao, L. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105825 · Cited by 7
Fatty acid metabolism influences the immune microenvironment in papillary thyroid cancer and identifies SCD as a novel biomarker
Shen, B., Zhang, Y., & Tie, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1534393 · Cited by 7
“The ACC family in ﬂ uences tumor progression, with ACACB being an important member of this family (44, 45).”
The Effect of Nutrition Education Program on Overweight/Obese Patients with Non-Alcoholic Fatty Liver Disease: a Single-Blind Parallel Randomized Controlled Trial
Arab, A., Hadi, A., Moosavian, S. P., Rafie, N., & Hajianfar, H. (2019) · Clinical Nutrition Research · doi:10.7762/cnr.2019.8.3.238 · Cited by 7
“In addition to hepatic dysfunctions, other metabolic abnormalities have been increased paralleled with NAFLD such as type 2 diabetes mellitus (T2DM), cardiovascular disease and dyslipidemia [4].”
Background
Mitochondrial Energy-Regulating Effect of Atractyloside Inhibits Hepatocellular Steatosis Through the Activation of Autophagy
Zhang, P., Li, L., Sun, H., Zhang, Y., Zhang, G., Zhang, T., & Zeng, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.575695 · Cited by 7
“Several new pharmacological strategies act broadly to alter energy balance or specifically inhibit key enzymes involved in lipid synthesis (Samuel and Shulman, 2018).”
Background
Ameliorative role of ellagic acid against acute liver steatosis in adult zebrafish experimental model
Aishwarya, V., Thiyagaraj, A., Subbiah, V., Solairaja, S., Sangaran, A., Ramalingam, S., & Venkatabalasubramanian, S. (2021) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2021.109061 · Cited by 7
LKB1 acts as a critical brake for the glucagon‐mediated fasting response
Acevedo‐Acevedo, S., Stefkovich, M. L., Kang, S. W. S., Cunningham, R. P., Cultraro, C. M., & Porat‐Shliom, N. (2022) · Hepatology Communications · doi:10.1002/hep4.1942 · Cited by 7
“During diseases such as NAFLD and type 2 diabetes, an inability to shut down this fasting response results in persistent gluconeogenesis and lipolysis,[37] despite adequate nutrient consumption.”
Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases
Jia, M.-Q., Guan, C., Tao, J., & Zhou, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5042762 · Cited by 7
Prostaglandin 2α Promotes Autophagy and Mitochondrial Energy Production in Fish Hepatocytes
Tian, J., Du, Y., Yu, E., Lei, C., Xia, Y. L., Jiang, P., Li, H., Zhang, K., Li, Z., Gong, W., et al. (2022) · Cells · doi:10.3390/cells11121870 · Cited by 7
“With rapid industrialization, obesity and fatty liver disease have become non-communicable diseases that threaten modern societies worldwide [1].”
Background
Profile of 5-HT2A receptor involved in signaling cascades associated to intracellular inflammation and apoptosis in hepatocytes and its role in carbon tetrachloride-induced hepatotoxicity
Zhang, Y., Wang, Y., Zhang, K., Liang, X., Guan, J. Z., Jin, J., Zhang, Y., Xu, F., Yang, L., & Fu, J. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110612 · Cited by 7
Bombax ceiba Linn. leaf extract rich in phenolic compounds to mitigate non-alcoholic fatty liver-related complications in experimental model
El‐Bana, M. A., Ashour, M. N., Rasheed, W. I., Diab, Y. M., & Medhat, D. (2023) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2021-0479 · Cited by 7
Bredemolic Acid Improves Cardiovascular Function and Attenuates Endothelial Dysfunction in Diet-Induced Prediabetes: Effects on Selected Markers
Akinnuga, A. M., Siboto, A., Khumalo, B., Sibiya, N. H., Ngubane, P. S., & Khathi, A. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/1936406 · Cited by 7
“Consequently, due to the increased conversion of TG to VLDL, HDL clearance increases and results in decreased plasma HDL concentration [31, 32].”
Background
The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial
Tonev, D., Shumbayawonda, E., Tetlow, L. A., Herdman, L., French, M., Rymell, S., Thomaides-Brears, H. B., Caseiro‐Alves, F., Castelo-Branco, M. S., Ferreira, C., et al. (2020) · JMIR Research Protocols · doi:10.2196/19189 · Cited by 7
Lipid droplet screen in human hepatocytes identifies TRRAP as a regulator of cellular triglyceride metabolism
Abbey, D., Conlon, D., Rainville, C., Elwyn, S., Quiroz‐Figueroa, K., Billheimer, J. T., Schultz, D., Hand, N. J., Cherry, S. R., & Rader, D. J. (2021) · Clinical and Translational Science · doi:10.1111/cts.12988 · Cited by 7
Non‐alcoholic Fatty Liver Disease and Insulin Resistance
Petersen, M. C., Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch37 · Cited by 10
Self-citation
Lipidomics random forest algorithm of seminal plasma is a promising method for enhancing the diagnosis of necrozoospermia
Deng, T., Wang, W., Fu, Z., Xie, Y., Zhou, Y., Pu, J., Chen, K., Yao, B., Li, X., & Yao, J. (2024) · Metabolomics · doi:10.1007/s11306-024-02118-x · Cited by 6
“Phospholipids on the mitochondrial membrane primarily consist of phosphatidylcholine (PC), phosphatidylethanolamine (PE), and cardiolipin (CL), accounting for approximately 40%, 30%, and 15% of the total lipid composition, respectively (Samuel & Shulman, 2018).”
Background
Probiotic Lactiplantibacillus plantarum Lb41 alleviates high-fat diet-induced nonalcoholic fatty liver disease in mice
Lee, N., Lee, Y., Shin, D.-S., Park, E., & Paik, H. (2025) · Nutrition · doi:10.1016/j.nut.2025.112735 · Cited by 6
Effects of the triglyceride-glucose index on non-alcoholic fatty liver disease: Causal evidence from longitudinal cohort studies
Cao, T., Ni, X., Halengbieke, A., Tang, J., Han, Y., Sun, F., Gao, B., Zheng, D., Yan, Y., & Yang, X. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.105813 · Cited by 7
Genetic depletion of adipose-derived Isthmin-1 causes hepatic steatosis
Reghupaty, S. C., Voilquin, L., Zhao, M., Narasimhan, R., Patel, A. N., Lone, J. B., Bielczyk-Maczyńska, E., Danneskiold‐Samsøe, N. B., Brown, T., Jiang, Z., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102172 · Cited by 6
“This observation aligns with established concepts in metabolic physiology wherein a shift in substrate availability, including glycerol, can enhance lipogenic pathways in the liver [32].”
ScRNA-seq combined with ATAC-seq analysis to explore the metabolic balance mechanism of CCl4-induced liver inflammatory injury
Liu, H., Zhang, Y., & Ning, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1600685 · Cited by 6
Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
Dong, W., Zhang, H., Mu, S., Shi, S., Zhang, J., & Xu, K. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70131 · Cited by 7
“18 Furthermore, mitochondrial dysfunction induced by IR disrupts hepatic fatty acid (FA) oxidation and transport, which in turn increases fat deposition.”
Obesity as a Whole-Body Regulatory Disorder: A Systems Biology Framework for Metaflammation, Accelerated Aging, and Colorectal Cancer Risk
Dutta, G., Mishra, P., Mishra, S. P., & Badhai, J. (2026) · Onco · doi:10.3390/onco6030031 · Cited by 7
“This is accompanied by increased release of inflammatory mediators and lipid metabolites into the circulation, thereby worsening metabolic dysfunction in peripheral tissues [34–36].”
Inulin alleviates HFD-induced NAFLD by hepatic macrophage polarization and lipid metabolism via gut-liver axis
Song, W., Hu, J., Zhu, L., Chen, B., Li, L., Cui, X., Zhang, T., Miao, Y., Su, K., Liu, C., et al. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250040 · Cited by 9
Mangiferin reduces high-starch diet-induced lipid accumulation and liver damage by modulating triglyceride metabolism in largemouth bass (Micropterus salmoides)
Zheng, Y., Lu, Q., Cao, J., Han, G., Liu, Y., Liu, H., Jin, J., Zhang, Z., Yang, Y., Zhu, X., et al. (2024) · Aquaculture Reports · doi:10.1016/j.aqrep.2024.102266 · Cited by 7
Mitochondrial targeted therapies in MAFLD
Lai, S., Tang, D., & Feng, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151498 · Cited by 10
A nomogram combining PPARγ expression profiles and clinical factors predicts survival in patients with hepatocellular carcinoma
Zhou, X., Chi, Y., Dong, Z., Tao, T., Zhang, X., Pan, W., & Wang, Y. (2021) · Oncology Letters · doi:10.3892/ol.2021.12581 · Cited by 6
A New Oral Model to Assess Postprandial Lactate Production Rate
Bonet, J., Galuppo, B., Santoro, N., & Man, C. D. (2021) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2021.3124143 · Cited by 6
The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD
Yang, Z., Yang, J., Cai, J., Zhang, X., Zhang, P., She, Z., & Li, H. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2406157 · Cited by 6
“disorders have been considered as main drivers of the occurrence and progression of NAFLD [2,27,28].”
Background
Estimation of fatty liver disease clinical role on glucose metabolic remodelling phenotypes and T2DM onset
Martínez‐Urbistondo, D., Huerta, A. E., Navarro‐González, D., Sánchez‐Íñigo, L., Fernández‐Montero, A., Landecho, M. F., Martínez, J. A., & Delgado, J. P. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14036 · Cited by 6
Discovery of non-peptide GLP-1r natural agonists for enhancing coronary safety in type 2 diabetes patients
Shakour, N., Hoseinpoor, S., Rajabian, F., Azimi, S. G., Iranshahi, M., Sadeghi‐Aliabadi, H., & Hadizadeh, F. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2298734 · Cited by 6
“The development of insulin resistance and the progressive buildup of adipose tissue in T2D lead to increased levels of free fatty acids (FFAs), ultimately resulting in fat accumulation across several organs, notably affecting cardiac health (Samuel & Shulman, 2018).”

Authors: Samuel, V. T., & Shulman, G. I.
Affiliations: United States Department of Veterans Affairs (US)
Howard Hughes Medical Institute (US)
Corresponding author: Samuel, Varman T.
Shulman, Gerald I.
ORCID: Samuel, Varman T.
Shulman, Gerald I.
Venue: Cell Metabolism
Publisher: Elsevier BV
Published: 2018-01
Volume: 27
Issue: 1
Pages: 22-41
ISSN: 1550-4131 (ISSN-L)
DOI: 10.1016/j.cmet.2017.08.002
PMC: PMC5762395
OpenAlex: W2752428556
Cited by: 745
References: 263
Citations by year: 2026: 72 · 2025: 84 · 2024: 90 · 2023: 109 · 2022: 88 · 2021: 91 · 2020: 81 · 2019: 71 · 2018: 50
FWCI: 7.61
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 374 d)
Locations: Cell Metabolism (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Celgene
Novo Nordisk
National Institutes of Health (DK-40936, DK-45735, DK-R01 DK 11398401)
AstraZeneca
Gilead Sciences
Merck
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: non-alcoholic fatty liver disease, hepatic insulin resistance, diacylglycerol, protein kinase C epsilon, insulin receptor, glycogen synthesis, lipogenesis, gluconeogenesis, pyruvate carboxylase, bariatric surgery, weight loss, PPAR agonists, farnesoid X receptor, FGF21, glucagon-like peptide-1, acetyl-CoA carboxylase, stearoyl-CoA desaturase, mitochondrial uncoupling, therapeutic target
MeSH terms: Animals, Glucose, Humans, Insulin, Insulin Resistance, Metabolic Diseases, Lipid Metabolism, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks